The dopamine
receptor antagonist domperidone, which may increase milk production in
lactating women, is associated with serious cardiac risks, and should not be
used for lactation enhancement, according to a commentary published in the June
issue of Obstetrics and Gynecology.
Catherine A.
Sewell, MD, MPH, from the U.S. Food and Drug Administration in Silver Spring,
Maryland, and colleagues published this commentary to discuss the safety issues
associated with use of domperidone and to raise the awareness among healthcare
providers in US against the use of domperidone as galactagogue.
Although domperidone is approved in several countries outside the U.S. to treat certain gastric disorders, it is not approved in any country, including the U.S., for enhancing breast milk production in lactating women and is also not approved in the U.S. for any indication.
Although domperidone is approved in several countries outside the U.S. to treat certain gastric disorders, it is not approved in any country, including the U.S., for enhancing breast milk production in lactating women and is also not approved in the U.S. for any indication.
According to a release by FDA “The serious
risks associated with domperidone include cardiac arrhythmias, cardiac arrest,
and sudden death. These risks are related to the blood level of domperidone,
and higher levels in the blood are associated with higher risks of these
events.”
The U.S. Food and Drug Administration
(FDA) issued an import alert in 2004, updated in 2016, explaining that the
importation of domperidone is illegal with limited exceptions, including when
imported pursuant to an investigational new drug application.
A public safety warning has already
been issued for domperidone, as the drug is sometimes illegally obtained from other
countries and used to enhance milk production.
Only scant evidence exists to support its
use as lactation enhancer but considerable information exists on domperidone's
cardiac risks including QT prolongation, torsades de pointes, and sudden
cardiac death, including among lactating women.
“In light of limited efficacy data
that do not offset safety concerns from a public health perspective, we
continue to caution against using domperidone for lactation enhancement,” the
commentary states.
The FDA warning release can be
accessed here.
No comments:
Post a Comment